The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 June 2026•

1 min read

FDA Approval of Viridian's Lumvoa Intensifies Competition with Amgen's Tepezza in Thyroid Eye Disease

Key Facts

1The FDA approved Viridian Therapeutics' drug Lumvoa for thyroid eye disease.

2Analysts see Lumvoa having a competitive edge over Amgen's Tepezza due to shorter infusion time, fewer infusions, and broader label.

In the specialized biopharmaceutical market, competition for thyroid eye disease treatments has intensified following the FDA's approval of Viridian Therapeutics' Lumvoa. The decision adds a significant new therapeutic option, with analysts highlighting Lumvoa's competitive edge over Amgen's Tepezza due to shorter infusion time, fewer doses, and a broader label covering both active and chronic disease forms.

The approval comes as major pharma companies seek to expand in rare-disease markets. Per market data, Amgen closed at $360.55 on June 29, 2026, trading in a range of $358.46–$363.11. Analysts project substantial Lumvoa revenue growth by 2035, and Viridian is developing an experimental subcutaneous formulation for chronic patients.

From a trading perspective, Amgen shares at $360.55 sit near the June 29 high of $363.11, which may cap near-term gains absent additional catalysts. Markets await Amgen's competitive response—whether via Tepezza pricing adjustments or an improved formulation—along with updates from Viridian's subcutaneous clinical trials.